search

Active clinical trials for "Brain Neoplasms"

Results 1151-1160 of 1541

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Brain Metastases

This phase II trial is studying how well pemetrexed disodium works in treating patients with Lung Adenocarcinoma With Brain Metastases

Unknown status30 enrollment criteria

The Effect of Cerebral Oxygenation on Postoperative Recovery in Intracranial Surgery

Intracranial Neoplasm

The aim of this study was to investigate the effect of cerebral oxygenation on postoperative compilation in intracranial surgery.

Unknown status8 enrollment criteria

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Nonsmall Cell Lung CancerBrain Metastases

To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

Unknown status18 enrollment criteria

Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC

Non-small Cell Lung Cancer

Observe the effect os radiotherapy plus or not plus endostar in the treatment of brain metastasis in NSCLC

Unknown status2 enrollment criteria

HFSRT With Concurrent TMZ for Large BMs

Brain MetastasesChemotherapy1 more

A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.

Unknown status13 enrollment criteria

Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection...

Brain Tumor - MetastaticBrain Tumor1 more

Hyperosmotic agents are used to decrease intracranial pressure. The aim of the study is to compare the effects of continuous 3% hypertonic saline (HS), bolus HS and 20% mannitol on intraoperative brain relaxation in patients with raised intracranial pressure during surgery for supratentorial tumors.

Unknown status8 enrollment criteria

Central Nervous System(CNS) Efficacy of Dacomitinib

Non Small Cell Lung CancerBrain Metastases

This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.

Unknown status18 enrollment criteria

A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung...

Lung Cancer and Breast Cancer Patients With Brain Metastases

Brain metastasis (BM) is among the most feared complications in cancer because even small tumors may cause incapacitating neurologic symptoms. It is observed in more than 50% of patients with lung cancer and 15% to 25% of patients with breast cancer. Temozolomide (TMZ) is an oral alkylating agent that crosses blood-brain barrier (BBB). This pilot study aims to evaluate the efficacy, safety and tolerability of whole-brain radiotherapy (WBRT) plus concomitant TMZ in lung cancer and breast cancer patients with BM.

Unknown status18 enrollment criteria

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory...

Recurrent Childhood Brain Tumor

This research study is a Feasibility clinical trial. In this trial, researchers are trying to figure out whether a medication can be chosen based on rapid testing done on tumor tissue. Information from a feasibility or pilot trial will hopefully help researchers plan larger trials in the future to determine the effect of this therapy.

Unknown status33 enrollment criteria

Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents...

Brain Tumor

The outcome of pediatric refractory or relapsed brain tumor is very dismal. Standard chemotherapy showed poor response to these patients. Although tandem high dose chemotherapy with hematopoietic progenitor stem cell rescues has been chosen as a potentially curative therapy for long term survival and better outcome is expected if tumor burden before transplantation reduced by chemotherapy, effective salvage chemotherapy for tumor reduction is not established yet. Irinotecan is a recently developed topoisomerase I inhibitor, and there are preclinical and phase I, II data which proved practical effects in brain tumors. In those studies, irinotecan was administered alone or in combination with one other drug. Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols for brain tumors but the result was very poor in refractory or relapsed cases. However, irinotecan can be effective with these multiple chemotherapeutic agents. According to the pilot study of irinotecan in combination with vincristine, etoposide, carboplatin and cyclophosphamide in the investigators center, 75% percent of total 12 patients reached more than stable disease, and 2 patients got long term complete remission only with this multi-agent combination chemotherapy. But the combination of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is not clinically studied yet especially for pediatric patients. To improve response rate and progression-free survival, the combination chemotherapy of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is designed for pediatric refractory or relapsed brain tumor.

Unknown status14 enrollment criteria
1...115116117...155

Need Help? Contact our team!


We'll reach out to this number within 24 hrs